Becton Dickinson and Co (NYSE:BDX) EVP Betty D. Larson sold 1,700 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $224.97, for a total value of $382,449.00. Following the completion of the transaction, the executive vice president now directly owns 11,493 shares in the company, valued at approximately $2,585,580.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
NYSE:BDX opened at $225.41 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The stock has a market cap of $60.36 billion, a P/E ratio of 20.47, a price-to-earnings-growth ratio of 1.68 and a beta of 1.16.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The firm had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter last year, the business posted $2.65 earnings per share. The firm’s revenue was down .6% on a year-over-year basis. As a group, research analysts anticipate that Becton Dickinson and Co will post 11.69 EPS for the current year.
Several research firms have recently commented on BDX. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. Barclays increased their target price on Becton Dickinson and from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Monday, April 15th. Raymond James cut their target price on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research report on Tuesday, March 19th. Finally, TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus target price of $255.31.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CWM LLC grew its holdings in Becton Dickinson and by 5.6% during the 4th quarter. CWM LLC now owns 830 shares of the medical instruments supplier’s stock valued at $187,000 after buying an additional 44 shares in the last quarter. Providence Capital Advisors LLC lifted its stake in shares of Becton Dickinson and by 0.5% in the 4th quarter. Providence Capital Advisors LLC now owns 10,240 shares of the medical instruments supplier’s stock valued at $2,307,000 after purchasing an additional 48 shares during the last quarter. Cigna Investments Inc. New lifted its stake in shares of Becton Dickinson and by 0.6% in the 4th quarter. Cigna Investments Inc. New now owns 7,891 shares of the medical instruments supplier’s stock valued at $1,778,000 after purchasing an additional 48 shares during the last quarter. Ledyard National Bank lifted its stake in shares of Becton Dickinson and by 2.3% in the 4th quarter. Ledyard National Bank now owns 2,268 shares of the medical instruments supplier’s stock valued at $511,000 after purchasing an additional 50 shares during the last quarter. Finally, Wesbanco Bank Inc. lifted its stake in shares of Becton Dickinson and by 3.7% in the 4th quarter. Wesbanco Bank Inc. now owns 1,389 shares of the medical instruments supplier’s stock valued at $313,000 after purchasing an additional 50 shares during the last quarter. Institutional investors and hedge funds own 85.24% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (BDX) EVP Sells $382,449.00 in Stock” was originally published by WKRB News and is owned by of WKRB News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.wkrb13.com/2019/05/16/becton-dickinson-and-co-bdx-evp-sells-382449-00-in-stock.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: What is Blockchain?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.